Cat. No.: HY-16928

Cytochalasin B

(Synonyms: Phomin)

46 Cited Publications

Customer Review

Based on 46 publication(s) in Google Scholar

Cytochalasin B is a cell-permeable mycotoxin binding to the barbed end of actin filaments, disrupting the formation of actin polymers, with K_d value of 1.4-2.2 nM for F-actin. Cytochalasin B blocks cell migration.

For research use only. We do not sell to patients.

Purity: 99.55%
CAS No.: 14930-96-2
Formula: C₂₉H₃₇NO₅
Molecular Weight:479.61

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Cytochalasin B Chemical Structure

CAS No.: 14930-96-2

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (46)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

Kd: 2.2 nM (F-actin, with Mg²⁺), 1.4 nM (F-actin, with Mg²⁺/K⁺)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	2.13 μM Compound: 5	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 22483395]
CHO	IC₅₀	0.26 μg/mL Compound: Cytochalasin B	Cytotoxicity against CHO cells transfected with ICAM1 by MTT assay Cytotoxicity against CHO cells transfected with ICAM1 by MTT assay	[PMID: 15165136]
HCT-116	IC₅₀	12 μM Compound: 8	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34846891]
HCT-15	IC₅₀	1.94 μM Compound: 5	Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay	[PMID: 22483395]
HEK293	IC₅₀	>10 μM Compound: 5311281	Inhibition of the Glucose Transporter (GLUT2, SLC2A2) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A2 WT-OE cells Inhibition of the Glucose Transporter (GLUT2, SLC2A2) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A2 WT-OE cells	10.5281/zenodo.7360664
HEK293	IC₅₀	>10 μM Compound: 5311281	Inhibition of the Glucose Transporter (GLUT2, SLC2A2) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A2 WT-OE cells (PubChem AID: 1794829) Inhibition of the Glucose Transporter (GLUT2, SLC2A2) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A2 WT-OE cells (PubChem AID: 1794829)	10.5281/zenodo.7360664
HEK293	IC₅₀	3.9 μM Compound: 5311281	Inhibition of the Glucose Transporter (GLUT4, SLC2A4) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A4 WT-OE cells Inhibition of the Glucose Transporter (GLUT4, SLC2A4) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A4 WT-OE cells	10.5281/zenodo.7360638
HEK293	IC₅₀	3.9 μM Compound: 5311281	Inhibition of the Glucose Transporter (GLUT3, SLC2A3) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A3 WT-OE cells Inhibition of the Glucose Transporter (GLUT3, SLC2A3) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A3 WT-OE cells	10.5281/zenodo.7360656
HEK293	IC₅₀	3.9 μM Compound: 5311281	Inhibition of the Glucose Transporter (GLUT4, SLC2A4) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A4 WT-OE cells (PubChem AID: 1794828) Inhibition of the Glucose Transporter (GLUT4, SLC2A4) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A4 WT-OE cells (PubChem AID: 1794828)	10.5281/zenodo.7360638
HEK293	IC₅₀	3.9 μM Compound: 5311281	Inhibition of the Glucose Transporter (GLUT3, SLC2A3) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A3 WT-OE cells (PubChem AID: 1794827) Inhibition of the Glucose Transporter (GLUT3, SLC2A3) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A3 WT-OE cells (PubChem AID: 1794827)	10.5281/zenodo.7360656
HEK293	IC₅₀	4.1 μM Compound: 5311281	Inhibition of the Glucose Transporter (GLUT1, SLC2A1) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A1 WT-OE cells Inhibition of the Glucose Transporter (GLUT1, SLC2A1) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A1 WT-OE cells	10.5281/zenodo.7360676
HEK293	IC₅₀	4.1 μM Compound: 5311281	Inhibition of the Glucose Transporter (GLUT1, SLC2A1) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A1 WT-OE cells (PubChem AID: 1794830 Inhibition of the Glucose Transporter (GLUT1, SLC2A1) as assessed by a FRET based flow cytometry assay using a genetically-encoded biosensor for measuring free glucose (FLII12Pglu-700uDelta6) in HEK293 JumpIN TRex SLC2A1 WT-OE cells (PubChem AID: 1794830	10.5281/zenodo.7360676
HeLa	IC₅₀	0.25 μg/mL Compound: Cytochalasin B	Inhibition of LFA1/ICAM1-mediated CFSE-labeled TPA-stimulated human HL60 cell adhesion to ICAM1 expressing human HeLa cells after 45 mins by fluorescence analysis Inhibition of LFA1/ICAM1-mediated CFSE-labeled TPA-stimulated human HL60 cell adhesion to ICAM1 expressing human HeLa cells after 45 mins by fluorescence analysis	[PMID: 11374943]
HeLa	IC₅₀	5.5 μg/mL Compound: cytochalasin B	Inhibition of LFA1:CD11a/CD18/ICAM1-mediated human HL60 cell adhesion to human HeLa cells expressing ICAM1 by fluorescence analysis Inhibition of LFA1:CD11a/CD18/ICAM1-mediated human HL60 cell adhesion to human HeLa cells expressing ICAM1 by fluorescence analysis	[PMID: 12880315]
HeLa	IC₅₀	7.9 μM Compound: 5	Cytotoxicity against human HeLa cells after 48 hrs by SRB assay Cytotoxicity against human HeLa cells after 48 hrs by SRB assay	[PMID: 22483395]
HepG2	IC₅₀	9.5 μM Compound: 8	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34846891]
HL-60	IC₅₀	>30 μg/mL Compound: Cytochalasin B	Cytotoxicity against human HL60 cells after 7 days by XTT/PMS assay Cytotoxicity against human HL60 cells after 7 days by XTT/PMS assay	[PMID: 11374943]
HL-60	IC₅₀	>30 μg/mL Compound: cytochalasin B	Cytotoxicity against human HL60 cells by XTT assay Cytotoxicity against human HL60 cells by XTT assay	[PMID: 12880315]
HL-60	IC₅₀	40 μg/mL Compound: Cytochalasin B	Cytotoxicity against human HL60 cells by XTT assay Cytotoxicity against human HL60 cells by XTT assay	[PMID: 15165136]
HL-60	IC₅₀	7.1 μg/mL Compound: Cytochalasin B	Inhibition of LFA1/ICAM1-mediated adhesion of HL60 cells to CHO-ICAM1 cells Inhibition of LFA1/ICAM1-mediated adhesion of HL60 cells to CHO-ICAM1 cells	[PMID: 15165136]
MCF7	IC₅₀	5.2 μM Compound: 8	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 34846891]
MRC5	IC₅₀	0.27 μM Compound: 1; CytB	Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 72 hrs by WST-1 assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth incubated for 72 hrs by WST-1 assay	[PMID: 38283219]
RAW264.7	IC₅₀	5.6 μg/mL Compound: Cytochalasin B	Inhibition of iNOS production in LPS-activated mouse RAW264.7 cells after 20 hrs Inhibition of iNOS production in LPS-activated mouse RAW264.7 cells after 20 hrs	[PMID: 15165136]
RAW264.7	IC₅₀	6.5 μg/mL Compound: Cytochalasin B	Cytotoxicity against mouse RAW264.7 cells after 2 days by MTT assay Cytotoxicity against mouse RAW264.7 cells after 2 days by MTT assay	[PMID: 15165136]
SK-MEL-2	IC₅₀	0.67 μM Compound: 5	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 22483395]
SK-OV-3	IC₅₀	0.46 μM Compound: 5	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 22483395]
XF498	IC₅₀	2.36 μM Compound: 5	Cytotoxicity against human XF498 cells after 48 hrs by SRB assay Cytotoxicity against human XF498 cells after 48 hrs by SRB assay	[PMID: 22483395]

In Vitro

Cytochalasin B is a cell-permeable mycotoxin binding to the barbed end of actin filaments, inhibits the enlongation and shortening of actin filaments, with K_ds of 2.2 nM and 1.4 nM for F-actin in the presence of MgCl₂ (2 mM) or MgCl₂ (2 mM) plus KCl, respectively^[1]. Cytochalasin B (0.1-10 μM) shows inhibitory effect on multiple murine cancer cell lines, with IC₅₀s of 2.56 μM (M109c), 10.46 μM (B16BL6), 105.5 μM (P388/ADR), 51.9 μM (P388/S) and IC₈₀s of 12.23 μM (M109c), 44.86 μM (B16BL6), 188.4 μM (P388/ADR), 84.1 μM (P388/S) after treatment for 3 h, with IC₅₀s of 0.25 μM (M109c), 0.37 μM (B16F10), 0.87 μM (B16BL6), and IC₈₀s of 0.75 μM (M109c), 1.21 μM (B16F10), 10.41 μM (B16BL6) after treatment for 4 days^[2]. Cytochalasin B (6 μM) increases the myofibrillar fragmentation index (MFI), which is attributed to the intensely breaking of myofibrillar proteins into short segments. Cytochalasin B also accelerates the disruption of actin filaments. In addition, Cytochalasin B accelerates the transformation from F-actin to G-actin, lowering the content of F-actin and significantly increasing G-actin bands during postmortem conditioning^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cytochalasin B (10, 25, 50 mg/kg, i.p.) dose-dependently increases the life expectancy of Balb/c mice bearing with P388/ADR leukemias. Cytochalasin B at 50 mg/kg produces 10 % long-term survival in the multidrug resistant P388/ADR cohort, and 40 % long-term survival in the drug sensitive P388/S cohort^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 14930-96-2
Appearance Solid
Molecular Weight 479.61
Formula C₂₉H₃₇NO₅
Color White to off-white
SMILES

O=C1N[C@@H](CC2=CC=CC=C2)[C@@]3([H])[C@]14[C@](/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(O4)=O)([H])[C@H](O)C([C@H]3C)=C
Synonyms

Phomin
Structure Classification
- Others
Initial Source
- Microorganisms
Mould
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (46)

All Cell Proliferation/Viability AssayIFCell Imaging/StainingELISAWB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape. [Abstract]

2023 Dec 25;8(1):457. PMID: 38143263

Cytochalasin B purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Dec 25;8(1):457. [Abstract]

U87 cells with high EGFRvIII density were cocultured with EGFRvIII-targeted CAR-T cells, supplemented with indicated drugs. Cells were magnetically separated for CAR molecule detection. Representative immunoblotting images from three independent duplications showed that Atorvastatin (5μM, 3 days) and Cytochalasin (10μg/mL, 1 day) alleviated CAR molecule transfer.
Nat Commun

Nuclear membrane protein SUN2 promotes replication of flaviviruses through modulating cytoskeleton reorganization mediated by NS1. [Abstract]

2024 Jan 5;15(1):296. PMID: 38177122
Nat Commun

CD36 inhibits β-catenin/c-myc-mediated glycolysis through ubiquitination of GPC4 to repress colorectal tumorigenesis. [Abstract]

2019 Sep 4;10(1):3981. PMID: 31484922

Cytochalasin B purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Sep 4;10(1):3981. [Abstract]

Cell viability of SW480 and LoVo cells was measured by MTT assays with Cytochalasin B (20 μM, 48 h).
Adv Sci (Weinh)

APOL2 Stabilizes Ku80 to Confer NHEJ-Mediated Radioresistance in Gastric Cancer. [Abstract]

2025 Sep 15:e06294. PMID: 40953331
Adv Sci (Weinh)

Microfilament-Myosin II Regulates the Differentiation of Multinucleated Cysts into Oocytes and Influences Oocyte Developmental Potential in Mice. [Abstract]

2025 Sep 17:e00358. PMID: 40959902
Adv Sci (Weinh)

Gelsolin's Protective Role in MASH through F-Actin Regulation and P53 Degradation. [Abstract]

2025 May 20:e2416489. PMID: 40390546
Adv Sci (Weinh)

Heterogeneous Responses to Mechanical Force of Prostate Cancer Cells Inducing Different Metastasis Patterns. [Abstract]

2020 Jun 17;7(15):1903583. PMID: 32775149

Cytochalasin B purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Jun 17;7(15):1903583. [Abstract]

Fluorescence imaging of LNCaP cells treated with the F-actin inhibitor cytoskeleton B (CB), microtubule inhibitor nocodazole (NO), FAK inhibitor PF573288 (PF), ROCK inhibitor Y-27632 (Y), and myosin II (Myo-II) inhibitor (-)-blebbistatin ((-)Bl). After the cells were cultured on different substrates for 3 days, inhibitors were added and incubated for 24 h. (green, F-actin; scale bar, 25 µm).

Cytochalasin B purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2020 Jun 17;7(15):1903583. [Abstract]

Expression of CTC cluster-related (plakoglobin and CD44) and EMT-related (vimentin and E-cadherin, 4 days) proteins in LNCaP cells grown on different substrates after treatment with different inhibitors (Cytoskeleton B (CB), Nocodazole (NO), PF-573288 (PF), Y-27632 (Y), and (-)-Blebbistatin ((-) Bl)).
Theranostics

ROCK inhibitor enhances mitochondrial transfer via tunneling nanotubes in retinal pigment epithelium. [Abstract]

2024 Sep 9;14(15):5762-5777. PMID: 39346535

Cytochalasin B purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Sep 9;14(15):5762-5777. [Abstract]

ARPE19-mito-GFP cells (green) co-cultured with ARPE19 cells (blue) in control and Y-27632 groups were treated with Cytochalasin B (10µM, 24h).
Chem Eng J

2025 Sep 4;522:168081.

Cytochalasin B purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 Sep 4;522:168081.

Fluorescence image of MSC^CXCR4/PSGL-1 showing the production of MVs induced by Cytochalasin B (10 μg/mL, 30 min).
J Nanobiotechnology

Dynamic three-dimensional culture enhances tunneling nanotubes-mediated mitochondrial transfer in mesenchymal stromal cells to accelerate wound healing. [Abstract]

2025 Aug 11;23(1):559. PMID: 40790215
Cell Discov

Loss-of-function variants in ODAD1 disrupt ODA docking and induce actin cytoskeletal remodeling in primary ciliary dyskinesia. [Abstract]

2026 Mar 31;12(1):25. PMID: 41916967
Cell Rep Med

Taxane chemotherapy promotes response to TIM-3 checkpoint blockade via STING-mediated ER stress and HMGB1 secretion. [Abstract]

2026 May 19;7(5):102788. PMID: 42097146
Mater Today Bio

Melatonin-loaded bioactive microspheres accelerate aged bone regeneration by formation of tunneling nanotubes to enhance mitochondrial transfer. [Abstract]

2024 Aug 2:28:101175. PMID: 39171100
Cell Commun Signal

Estradiol increases risk of topoisomerase IIβ-mediated DNA strand breaks to initiate Xp11.2 translocation renal cell carcinoma. [Abstract]

2021 Nov 16;19(1):114. PMID: 34784933
Cell Commun Signal

Pathogenic effects of inhibition of mTORC1/STAT3 axis facilitates Staphylococcus aureus-induced pyroptosis in human macrophages. [Abstract]

2020 Nov 30;18(1):187. PMID: 33256738

Cytochalasin B purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2020 Nov 30;18(1):187. [Abstract]

Expression of pyroptosis-related proteins in response to S. aureus invasion and Cytochalasin B (10 μg/mL, 30 min) was assessed by western blot in THP-1.

Cytochalasin B purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2020 Nov 30;18(1):187. [Abstract]

The levels of IL-18 and IL-1β were quantified by an ELISA in THP-1, and the levels of IL-18 and IL-1β were less prominent than S. aureus invasion after Cytochalasin B （10 μg/mL, 30 min） treated.
Environ Sci Technol Lett

2023 Sep 27.
Dev Cell

STAT3-controlled CHI3L1/SPP1 positive feedback loop demonstrates the spatial heterogeneity and immune characteristics of glioblastoma. [Abstract]

2025 Jun 23;60(12):1751-1767.e9. PMID: 39933531
Acta Pharmacol Sin

GPR84 regulates pulmonary inflammation by modulating neutrophil functions. [Abstract]

2023 Aug;44(8):1665-1675. PMID: 37016043
Free Radic Biol Med

Macrophages induce cardiomyocyte ferroptosis via mitochondrial transfer. [Abstract]

2022 Sep:190:1-14. PMID: 35933052
Environ Pollut

Associations of welding-related metals and hypertension in male welders: Roles of cytokinesis-block micronucleus cytome assay parameters. [Abstract]

2025 Mar 24:126119. PMID: 40139295
Cell Rep

Mechanotransduction in response to ECM stiffening impairs cGAS immune signaling in tumor cells. [Abstract]

2023 Oct 5;42(10):113213. PMID: 37804510
NPJ Regen Med

Cyclic pulsation stress promotes bone formation of tissue engineered laminae through the F-actin/YAP-1/β-Catenin signaling axis. [Abstract]

2021 Sep 6;6(1):51. PMID: 34489466
Cell Biol Toxicol

TRAF6 promotes spinal microglial M1 polarization to aggravate neuropathic pain by activating the c-JUN/NF-kB signaling pathway. [Abstract]

2024 Jul 12;40(1):54. PMID: 38995476
Cell Prolif

The mitochondrial-endoplasmic reticulum co-transfer in dental pulp stromal cell promotes pulp injury repair. [Abstract]

2024 Jan;57(1):e13530. PMID: 37493094
Cell Prolif

Intercellular mitochondrial transfer alleviates pyroptosis in dental pulp damage. [Abstract]

2023 Sep;56(9):e13442. PMID: 37086012
Int J Mol Sci

Cytochalasin B Mitigates the Inflammatory Response in Lipopolysaccharide-Induced Mastitis by Suppressing Both the ARPC3/ARPC4-Dependent Cytoskeletal Changes and the Association Between HSP70 and the NLRP3 Inflammasome. [Abstract]

2025 Mar 26;26(7):3029. PMID: 40243637
J Mol Cell Cardiol

Novel signaling axis of FHOD1-RNF213-Col1α/Col3α in the pathogenesis of hypertension-induced tunica media thickening. [Abstract]

2023 Sep:182:57-72. PMID: 37482037
Reprod Biol Endocrinol

Rapamycin improves the quality and developmental competence of mice oocytes by promoting DNA damage repair during in vitro maturation. [Abstract]

2022 Apr 18;20(1):67. PMID: 35436937
RSC Adv

Dual inhibitory potential of ganoderic acid A on GLUT1/3: computational and in vitro insights into targeting glucose metabolism in human lung cancer. [Abstract]

2024 Sep 6;14(39):28569-28584. PMID: 39247503
Antimicrob Agents Chemother

Inhibitory Effect of PIK-24 on Respiratory Syncytial Virus Entry by Blocking Phosphatidylinositol-3 Kinase Signaling. [Abstract]

2020 Sep 21;64(10):e00608-20. PMID: 32718963
Front Cell Dev Biol

Homozygous Loss of Septin12, but not its Haploinsufficiency, Leads to Male Infertility and Fertilization Failure. [Abstract]

2022 Apr 25;10:850052. PMID: 35547809
Mol Neurobiol

SETD3 Downregulation Mediates PTEN Upregulation-Induced Ischemic Neuronal Death Through Suppression of Actin Polymerization and Mitochondrial Function. [Abstract]

2021 Oct;58(10):4906-4920. PMID: 34218417
J Cell Physiol

Ankrd1 inhibits the FAK/Rho-GTPase/F-actin pathway by downregulating ITGA6 transcriptional to regulate myoblast functions. [Abstract]

2024 Jul 10:e31359. PMID: 38988048
Sci Rep

Coal dust particles can upregulate the expression of NLRP3 inflammasome components in rat alveolar macrophages through phagocytosis. [Abstract]

2025 Mar 15;15(1):8989. PMID: 40089559
J Biol Chem

SARS-CoV-2 hijacks macropinocytosis to facilitate its entry and promote viral spike-mediated cell-to-cell fusion. [Abstract]

2022 Nov;298(11):102511. PMID: 36259516
Cytokine

Phagocyte extracellular traps formation contributes to host defense against Clostridium perfringens infection. [Abstract]

2023 Sep:169:156276. PMID: 37339556
Microb Pathog

Phosphorylation of silkworm thymosin promotes the proliferation of Bombyx mori nucleopolyhedrovirus by facilitating the assembly of microfilaments. [Abstract]

2026 Apr:213:108348. PMID: 41628838
Pathogens

Sputum from People with Cystic Fibrosis Reduces the Killing of Methicillin-Resistant Staphylococcus aureus by Neutrophils and Diminishes Phagosomal Production of Reactive Oxygen Species. [Abstract]

2023 Sep 9;12(9):1148. PMID: 37764956
Asian J Androl

Micronucleus counts correlating with male infertility: a clinical analysis of chromosomal abnormalities and reproductive parameters. [Abstract]

2025 Jul 1;27(4):537-542. PMID: 39789711
Platelets

Actin polymerization regulates glycoprotein Ibα shedding. [Abstract]

2022 Apr 3;33(3):381-389. PMID: 33979555
Tissue Cell

Characteristics of tunneling nanotube-like structures formed by human dermal microvascular pericytes in vitro. [Abstract]

2024 Jun 11:89:102431. PMID: 38870572
Mutat Res Genet Toxicol Environ Mutagen

Assessment of radiation doses and DNA damage in pediatric patients undergoing interventional procedures for vascular anomalies. [Abstract]

2023 Jul:889:503653. PMID: 37491112
Biochem Biophys Rep

Exosome-mediated transduction of mechanical force regulates prostate cancer migration via microRNA. [Abstract]

2022 Jul 2:31:101299. PMID: 35812347
Res Sq

2025 jun 19.
bioRxiv

Mitochondria redistribution organizes the immunosuppressive tumor ecosystem. [Abstract]

2025 Nov 13:2025.11.11.687895. PMID: 41292779
Journal of Dermatologic Science and Cosmetic Technology

2025 Jun.

Solvent & Solubility

In Vitro:

DMSO : 83.33 mg/mL (173.75 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 25 mg/mL (52.13 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0850 mL

10.4251 mL

20.8503 mL

5 mM

0.4170 mL

2.0850 mL

4.1701 mL

10 mM

0.2085 mL

1.0425 mL

2.0850 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.21 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.21 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.21 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 5

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (4.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 6

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/0.5% Tween-80 in Saline water

Solubility: 5 mg/mL (10.43 mM); Suspened solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

The attached cell lines M109c, B16BL6, and B16F10 are seeded at 1 to 4 × 10⁴ cells/mL in 2 mL volumes in 24-well culture plates 1 day prior to treatment with Cytochalasin B. The suspension culture of P388/ADR cells is seeded at 5 × 10⁴ cells/mL and allowed to grow overnight before Cytochalasin B treatment. Cells are treated with Cytochalasin B for 3 h, as well as 2, 3, or 4 days. In the case of continuous exposure for 2, 3, or 4 days, attached cells are trypsinized and counted with a hemacytometer. Leukemia cell suspensions are counted with a Coulter Counter. In the case of short-term exposure, cells are washed twice with fresh medium, then trypsinized (except for P388/ADR cells), reseeded, and allowed to regrow for 3 days, at which time they are counted. Growth results are calculated as the number of cells generated above the seeding density compared to the untreated control cells and graphically presented as percent of control increase^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
For chemotherapy testing, Balb/c mice under isoflurane anesthesia are challenged with 2 × 10⁵ trypan blue negative P388/S or P388/ADR cells subcutaneously (s.c.) in a volume of 200 μL. Untreated mice are kept in order to determine the lethality of the challenge without chemotherapeutic intervention. Long-term survival is defined as challenged mice that survive the duration of the observation period. Cytochalasins B and D are prepared in suspension form in 2 % carboxymethyl cellulose 1 % tween 20 (CMC/Tw) for intraperitoneal (i.p.) administration. The congeners or the vehicle are administered to leukemia-challenged mice on Days 1-8 following the initial challenge^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (584 KB)
- English - EN (584 KB)
- Français - FR (584 KB)
- Deutsch - DE (584 KB)
- Norwegian - NO (584 KB)
- Español - ES (584 KB)
- Swedish - SV (584 KB)
- Italian - IT (584 KB)
- Portuguese - PT (584 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Theodoropoulos PA, et al. Cytochalasin B may shorten actin filaments by a mechanism independent of barbed end capping. Biochem Pharmacol. 1994 May 18;47(10):1875-81. [Content Brief]

[2]. Trendowski M, et al. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Invest New Drugs. 2015 Apr;33(2):290-9. [Content Brief]

[3]. Zhou C, et al. The effect of Cytochalasin B and Jasplakinolide on depolymerization of actin filaments in goose muscles during postmortem conditioning. Food Res Int. 2016 Dec;90:1-7. [Content Brief]

[4]. Liang Ma, et al. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. Cell Res. 2015 Jan;25(1):24-38. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	2.0850 mL	10.4251 mL	20.8503 mL	52.1257 mL
	5 mM	0.4170 mL	2.0850 mL	4.1701 mL	10.4251 mL
	10 mM	0.2085 mL	1.0425 mL	2.0850 mL	5.2126 mL
	15 mM	0.1390 mL	0.6950 mL	1.3900 mL	3.4750 mL
	20 mM	0.1043 mL	0.5213 mL	1.0425 mL	2.6063 mL
	25 mM	0.0834 mL	0.4170 mL	0.8340 mL	2.0850 mL
	30 mM	0.0695 mL	0.3475 mL	0.6950 mL	1.7375 mL
	40 mM	0.0521 mL	0.2606 mL	0.5213 mL	1.3031 mL
	50 mM	0.0417 mL	0.2085 mL	0.4170 mL	1.0425 mL
DMSO	60 mM	0.0348 mL	0.1738 mL	0.3475 mL	0.8688 mL
	80 mM	0.0261 mL	0.1303 mL	0.2606 mL	0.6516 mL
	100 mM	0.0209 mL	0.1043 mL	0.2085 mL	0.5213 mL

Keywords

Cytochalasin B

46 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Cytochalasin B

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Cytoskeleton Compound Library

Anti-Blood Cancer Compound Library

Microbial Metabolite Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Biotoxin Library

Natural Product Diversity Scaffold Library

Fungal-Sourced Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Cytochalasin B

Biological Activity

Chemical Information

Publications (46)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Cytochalasin B

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Lipid Compound Library

Cytoskeleton Compound Library

Anti-Blood Cancer Compound Library

Microbial Metabolite Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Biotoxin Library

Natural Product Diversity Scaffold Library

Fungal-Sourced Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Cytochalasin B

Biological Activity

Chemical Information

Publications (46)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Cytochalasin B Related Classifications

Cat. No.: HY-16928